TELESTA THERAPEUTICS INC T.TST

RE: RE: Redacted

[rhdmd]

Hello Dr. _____

 

As noted in the news release, the deal with Paladin is expected to close on or around June 14^th. Following the deal closure, we will be filing relevant documents on SEDAR where additional detail (if allowable) will be accessible to all shareholders. Hopefully, this will provide answers to most, if not all, of your questions below.

 

I can say that the economics of the revenue sharing arrangement with Paladin are significantly better than those under our previous licensing deal with Endo.

 

Sincerely,

Jennifer

 

Jennifer Shea

Vice-President, Communications, Investor & Government Relations

Bioniche Life Sciences Inc.

P.O. Box 1570, 231 Dundas St. E.

Belleville, Ontario

Canada  K8N 5J2

Phone: [phone] ext. 1250

Mobile: [phone]

Fax: [phone]

Email: [e-mail]

www.Bioniche.com